Epinomics - Part of 10x Genomics Revenue and Competitors

As announced in August 2018, Epinomics is now part of 10x Genomics. -------------------------------------------------------------------------------- Personalized medicine with “the living genome” - EPINOMICS If the genome is the hardware of our bodies, then the epigenome may be considered the software, since it regulates which genes get turned on and off. Because it dynamically responds to the environment and reflects an individual’s state of health at any given moment, the epigenome holds the key to personalized medicine. Scientists have long searched for ways to better understand the epigenome. In 2013, professors and researchers at Stanford University invented a breakthrough technology that can decode the epigenome. In order to further advance this cutting-edge technology, a start-up company, called Epinomics, was formed by Stanford professors and experienced leaders. Epinomics leverages the founders’ industry and leadership experience, as well as the talents of a strong scientific advisory board that includes Mike Snyder (Stanford Chair of Genetics Department), Joe Ecker (Salk International Council Chair in Genetics, HHMI), Anshul Kundaje (a leader of NIH-funded ENCODE and Epigenomics Roadmap consortia), and Robert Tibshirani (Professor in the Departments of Statistics and Health Research and Policy at Stanford). Using Epinomics’ technology and analytics platform, researchers in pharmaceutical / biotech industry and academia have begun to advance therapeutic development efforts, discovering biomarkers for use in clinical research and advancing immuno-oncology applications. This is enabling the development of more effective therapeutic strategies and improved outcomes for clinical trials and beyond. Epinomics' vision is to create a comprehensive map of human health states, and leverage epigenomics technology and deep analytics to develop a GPS to guide personalized health. Science contact: epi@epinomics.co